Tekla Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Tekla Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-41,577	Closed	-$1.08M	–	206
2020 Q4	$1.08M	Hold	41,577	–	–	0.04%	176
2020 Q3	$1.54M	Hold	41,577	–	–	0.06%	165
2020 Q2	$2.13M	Hold	41,577	–	–	0.08%	156
2020 Q1	$1.31M	Sell	41,577 -171,985	-81%	-$9.08M	0.06%	159
2019 Q4	$12.7M	Hold	213,562	–	–	0.48%	45
2019 Q3	$7.83M	Buy	213,562 +28,955	+16%	+$1.15M	0.34%	59
2019 Q2	$8.59M	Hold	184,607	–	–	0.35%	64
2019 Q1	$7.41M	Buy	184,607 +42,318	+30%	+$1.9M	0.3%	70
2018 Q4	$6.54M	Sell	142,289 -46,998	-25%	-$2.26M	0.28%	72
2018 Q3	$8.4M	Hold	189,287	–	–	0.3%	73
2018 Q2	$7.42M	Hold	189,287	–	–	0.28%	78
2018 Q1	$13.7M	Buy	+189,287	New	+$13.9M	0.53%	43
2017 Q1	–	Sell	-102,800	Closed	-$1.29M	–	142
2016 Q4	$1.29M	Hold	102,800	–	–	0.05%	123
2016 Q3	$1.42M	Hold	102,800	–	–	0.05%	127
2016 Q2	$1.02M	Hold	102,800	–	–	0.04%	146
2016 Q1	$1.74M	Hold	102,800	–	–	0.07%	125
2015 Q4	$2.29M	Hold	102,800	–	–	0.08%	117
2015 Q3	$2.42M	Sell	102,800 -45,200	-31%	-$2.84M	0.09%	137
2015 Q2	$12.1M	Buy	+148,000	New	+$14.5M	0.44%	48

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Tekla Capital Management's ESPR Position: Q1 2021 in Review

Tekla Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2021, closing a stake of 41,577 shares — an estimated $1.08M sold.

Tekla Capital Management first reported a position in ESPR in Q2 2015 and held it in 19 quarters. The position peaked at $13.7M in Q1 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q1 2021.

Tekla Capital Management reported no remaining Esperion Therapeutics position as of Q1 2021 after selling out during the quarter.
Tekla Capital Management sold 41,577 Esperion Therapeutics shares in Q1 2021, an estimated $1.08M.
Tekla Capital Management first reported a position in Esperion Therapeutics in Q2 2015 and held it in 19 quarters.
Tekla Capital Management's Esperion Therapeutics position peaked at $13.7M in Q1 2018.
155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.